Skip to main content
Clinical Trials/NCT05626894
NCT05626894
Recruiting
Phase 2

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Chronic Stroke Survivors

Spaulding Rehabilitation Hospital1 site in 1 country32 target enrollmentMarch 20, 2025

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Stroke
Sponsor
Spaulding Rehabilitation Hospital
Enrollment
32
Locations
1
Primary Endpoint
Change in Motor Activity Log-Amount of Use
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Detailed Description

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP). Study participants will be asked to take part in 4 evaluation study visits: one screening and enrollment visit, and three evaluation visits (at baseline, at 3 months and at 6 months - at the intervention completion). Subject upper-extremity motor function will be assessed across domains of the International Classification of Functioning, Disability and Health (ICF) model. Groups will be stratified by baseline motor impairment and stroke chronicity. Subjects randomized to the intervention group will take part of weekly coaching sessions during the first month, bi-weekly sessions during the months 2 and 3, and monthly sessions during months 4-6. These sessions will be held in-person or remotely, based on the study participant preference. Subjects randomized to the control group will take part of monthly visits, held in-person or remotely (based on study participant preference), to re-evaluate the home-exercise plan and prescribe an update list of exercises for the following month.

Registry
clinicaltrials.gov
Start Date
March 20, 2025
End Date
September 30, 2026
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Spaulding Rehabilitation Hospital
Responsible Party
Principal Investigator
Principal Investigator

Paolo Bonato

Director, Motion Analysis Laboratory

Spaulding Rehabilitation Hospital

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18-85 years of age at the time of enrollment;
  • Anterior circulation ischemic stroke at least 6 months and up to 5 years prior to study enrollment;
  • Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;
  • Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3 step command);
  • Being familiar and comfortable with the use of a tablet or smartphone.

Exclusion Criteria

  • Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;
  • Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see feedback on the app screen (as assessed with the star cancellation test);
  • Individuals with open wounds or recent fracture (less than 3 months) in the UE, fragile skin or active infection as evaluated by the study therapist;
  • Individuals currently enrolled in a UE rehabilitation program (i.e., OT, research study)
  • Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;
  • Diagnosis of other neurological disease (i.e., Parkinson's disease, multiple sclerosis, ...);
  • Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening as assessed by the study therapist;
  • Not understanding spoken or written English;
  • Recent (less than 3 months) Botox injection in the UE or plan to undergo injections during the study timeline;
  • Contralateral motor deficits as assessed by clinical examination;

Outcomes

Primary Outcomes

Change in Motor Activity Log-Amount of Use

Time Frame: Change from baseline Motor Activity Log-Amount of Use score at 6 months

Self-reported measure of upper-extremity performance. Score from 0 (worst) to 5 (best)

Change in Fugl-Meyer Upper-Extremity

Time Frame: Change from baseline Fugl-Meyer Upper-Extremity score at 6 months

Observed measure of upper-extremity motor impairment following a stroke. Score from 0 (worst) to 66 (best)

Change in Upper-Extremity Activity Counts

Time Frame: Change from baseline Upper-Extremity Activity Counts score at 6 months

Activity of the hemiparetic upper-extremity in the home setting as measured with wrist-worn accelerometers

Secondary Outcomes

  • Change in Motor Activity Log-Quality of Use(Change from baseline Motor Activity Log-Quality of Use score at 6 months)
  • Change in Stroke Impact Scale (SIS)(Change from baseline Stroke Impact Scale (SIS) score at 6 months)
  • Change in Wolf-Motor Function Test - Time subscale(Change from baseline Wolf-Motor Function Test - Time subscale score at 6 months)
  • Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale(Change from baseline Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale score at 6 months)
  • Change in Wolf-Motor Function Test - Functional ability subscale(Change from baseline Wolf-Motor Function Test - Functional ability subscale score at 6 months)
  • Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Self-management subscale(Change from baseline Self-Efficacy Questionnaire (SSEQ) - Self-management subscale score at 6 months)

Study Sites (1)

Loading locations...

Similar Trials